REFERENCES
- Anderson B. D., Wygant M. B., Xiang T., Waugh W. A., Stella V. J. Preformulation solubility and kinetic studies of 2′,3′-dideoxypurine nucleosides: potential anti-AIDS agents. Int. J. Pharm 1988; 45: 27–37
- Carstensen J. T., Rhodes C. T. Solution Kinetics. Drug Stability 3rd. Informa UK Ltd, New York 2000; 21–27
- ClogP for Windows, Version 4.0, 1995–1999 Biobyte Corp.
- Den Brok M. W. J., Nuijen B., Hillebrand M. J. X., Lutz C., Opitz H., Beijnen J. H. LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products. J. Pharm. Biomed 2005a; 38: 686–694
- Den Brok M. W. J., Nuijen B., Lutz C., Opitz H., Beijnen J. H. Pharmaceutical development of a lyophilized dosage form for the investigational anticancer agent imexon using dimethyl sulfoxide as a solubilizing and stabilizing agent. J. Pharm. Sci 2005b; 94(5)1101–1114
- Dvorakova K., Payne C. M., Tome M. E., Briehl M. M., McClure T., Dorr R. T. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent Imexon. Biochem. Pharmacol 2000; 60: 749–758
- Dvorakova K., Payne C. M., Tome M. E., Briehl M. M., Vasquez M. A., Waltmire C. N., Coon A., Dorr R. T. Molecular and cellular characterization of Imexon-resistant RPMI8226/I Myeloma Cells. Mole. Cancer Ther 2002; 1: 185–195
- Dvorakova K., Waltmire C. N., Payne C. M., Tome M. E., Briehl M. M., Dorr R. T. Induction of mitochondrial changers in myeloma cells by Imexon. Neoplasia 2001; 97(11)3544–3551
- Fubara J. O., Notari R. E. A Kinetic Oxymoron: Concentration-Dependent First-order rate constants for hydrolysis of Ceftazidime. J. Pharm. Sci 1998; 87(1)53–58
- Gribbon P., Sewing A. High-throughput drug discovery: what can we expect from HTS?. Drug Discovery Today 2005; 10(1)17–22
- Iyengar B. S., Dorr R. T., Alberts D. S., Hersh E. M., Salmon S. E., Remers W. A. Novel antitumor 2-Cyanoaziridine-1-carboxamides. J. Med. Chem 1999; 42: 510–514
- Iyengar B. S., Dorr R. T., Remers W. A. Chemical basis for the biological activity of Imexon and related Cyanaziridines. J. Med. Chem 2004; 47: 218–223
- Martin A., Swarbrick J., Cammarata A. Solubility and distribution phenomena. Physical Pharmacy 3rd. Informa UK Ltd, Philadelphia 1983
- Ni N., Sanghvi T., Yalkowsky S. H. Stabilization and preformulation of anticancer drug-SarCNU. Int. J. Pharm 2002; 249: 257–264
- Waterman K. C., Adami R. C. Accelerated aging: prediction of chemical stability of pharmaceuticals. Int. J. Pharm 2005; 293: 101–125
- Yalkowsky S. H. Solubillization by pH control. Solubility and Solubilization in Aqueous Media. Informa UK Ltd, New York 1999
- Zhu H., Meserve K., Floyd E. Preforumlation Studies for an ultrashort-acting neuromuscular blocking agent GW280430A. I. Buffer and cosolvent effects on the solution stability. Drug Dev. Int. Pharm 2002; 28(2)135–142